The focus of this virtual conference is to discuss precision medicine in atypical diabetes and in pregnancy, research updates regarding β cells in type 1 diabetes, and discuss therapeutic agents for those with type 2 diabetes and non-alcoholic fatty liver disease. These variables relate to what one needs in order to overcome challenges related to the diagnosis of diabetes.

The goal of this activity is to provide practitioners and scientists with a comprehensive overview of the depth and breadth of clinical and scientific endocrinology. November is National Diabetes Month and it is important to highlight and review evidence-based diabetes medicine.

TARGETED AUDIENCE

This activity has been designed for physicians, scientists, nurse practitioners, nurses, diabetes educators, students, and other healthcare professionals dedicated to the scientific advances in diabetes diagnosis, management, and treatment.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Identify precision medicine in atypical diabetes and opportunities to enroll patients to qualifying research studies;
• Recall the fundamentals of monogenic diabetes;
• Discuss the role of β cells in type 1 diabetes;
• State therapeutic agents that will benefit people with type 2 diabetes and non-alcoholic fatty liver disease;
• Identify key treatments in precision medicine for diabetes in pregnancy.

ACCREDITATION

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.